Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Prevention, Genetics
Results 1-25 of 50 for your search:
Start Over
Varenicline and Nicotine Replacement Therapy for Initial Smoking Cessation and Treatment in Smokers
Phase: Phase IV
Type: Behavioral study, Prevention
Age: 18 to 65
Trial IDs: 2014-0213, NCI-2015-00610, NCT02271919
Continuous or Intermittent Letrozole in Treating Postmenopausal Patients With Hormone Receptor-Positive Early Stage Breast Cancer
Phase: Phase III
Type: Prevention
Age: Postmenopausal
Trial IDs: 10-356, NCI-2011-00739, IBCSG-35-07, BIG-1-07-SOLE, EUDRACT-2007-001370-88, EU-20772, NCT00553410
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: CPP-FAP-310, NCI-2013-01805, NCT01483144
Metformin Hydrochloride with or without Lifestyle Intervention in Preventing Endometrial Cancer in Obese Post-Menopausal Patients with High Insulin Levels
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Age: 50 to 60
Trial IDs: 2011-0739, NCI-2013-00834, NCT01697566
Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
Topical or Ablative Treatment in Preventing Anal Cancer in Patients with HIV and Anal High-Grade Squamous Intraepithelial Lesions
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 35 and over
Trial IDs: AMC-A01, NCI-2014-00636, NCT02135419
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: 115523, NCI-2013-00630, 2012-000138-20, NCT01610414
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Prevention
Age: 40 to 120
Trial IDs: MC054A, NCI-2009-01192, 09-001758, NCT01647126, R01-CA-113681, NCT00983580
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 13 to 26
Trial IDs: AMC-072, NCI-2011-02510, CDR0000685816, NCT01209325
Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 and over
Trial IDs: 08218, NCI-2010-01976, 115422, NCT01196936
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 11-0265, NCI-2011-01246, NCT01414426
Dasatinib in Preventing Second Primary Breast Cancer in Women with Estrogen Receptor Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 2010-0794, NCI-2012-00037, KG09 1020, Susan Komen Foundation Grant Number(s): KG09 1020, NCT01471106
Fish Oil in Preventing Colorectal Cancer in Participants Previously Diagnosed with Colon Polyps
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 40 to 79
Trial IDs: VICC GI 14138, NCI-2015-00480, 11165, GI 14138, NCI-2015-00070, NCT01661764
Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 2011-0766, NCI-2013-00859, 12-267, 12-474, AAAK6752, H-33017, MSKCC-12-267, N01-CN-2012-00034, MDA10-16-01, NCT01849250
Pomegranate-Extract Pill in Preventing Tumor Growth in Patients with Localized Prostate Cancer Undergoing Active Surveillance
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 21 and over
Trial IDs: CO11378, NCI-2014-00695, N01-CN-2012-00033, UWI2013-00-01, NCT02095145
Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 1300000502, NCI-2014-01006, HHSN2612012000311, N01-CN-2012-00031, UAZ2013-01-01, NCT02123849
Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer
Phase: Phase II
Type: Prevention
Age: 50 to 80
Trial IDs: 13-000432, NCI-2014-01257, NCT02176902
Prostvac (PSA-TRICOM) in Preventing Disease Progression in Patients with Localized Prostate Cancer Undergoing Active Surveillance
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: 1410547210, NCI-2014-02556, AZ027, HHSN2612012000311, N01-CN-2012-00031, UAZ2014-03-01, NCT02326805
Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: UAZ2013-02-01, NCI-2015-00061, 1403269898, HHSN2612012000311, NCT02348203
Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients with Subsolid Lung Nodules
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 50 and over
Trial IDs: 2013-0732, NCI-2014-01311, 2013-004862-32, HHSN261201200034I, IEO 833/13F, IEO 833/13F (IEO37), MDACC-2013-0732, N01-CN-2012-00034, NCT02135497, MDA2013-01-01, NCT02169271
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue from Patients With Prostate Cancer Undergoing Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 40 to 75
Trial IDs: 12-000886, NCI-2013-01153, 12-000886-AM-00002, P30CA016042, R03CA171583, NCT01912820
Metformin Hydrochloride in Reducing Cancer Risk in Patients with Li-Fraumeni Syndrome
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 14-C-0005, NCI-2014-02320, 140005, P121103, NCT01981525
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients with Lynch Syndrome
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: 2013-0698, NCI-2014-00046, HHSN26100003; RFP B, HHSN261201200034I, MDACC-2013-0698, N01-CN-2012-00034, NCT02048735, MDA2013-01-02, NCT02052908
Start Over